Header Logo

Connection

Mohammed Rassool to Everolimus

Back to Details
This is a "connection" page, showing publications Mohammed Rassool has written about Everolimus.
Mohammed Rassool
Connection Strength
0,186
Everolimus
  1. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med. 2021 08; 9(8):897-908.
    View in: PubMed
    Score: 0,186
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.